RT Journal Article
SR Electronic
T1 Estimating the cure rate and case fatality rate of the ongoing epidemic COVID-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.18.20024513
DO 10.1101/2020.02.18.20024513
A1 Diao, Ying
A1 Liu, Xiaoyun
A1 Wang, Tao
A1 Zeng, Xiaofei
A1 Dong, Chen
A1 Zhang, Yuanming
A1 Zhou, Changlong
A1 She, Xuan
A1 Liu, Dingfu
A1 Hu, Zhongli
YR 2020
UL http://medrxiv.org/content/early/2020/02/20/2020.02.18.20024513.abstract
AB The epidemic caused by the novel coronavirus COVID-19 in Wuhan at the end of 2019 has become an urgent public event of worldwide concern. However, due to the changing data of the epidemic, there is no scientific estimate of the cure rate and case fatality rate of the epidemic. This study proposes a method to estimate the cure rate and case fatality rate of COVID-19. The ratio of cumulative discharges on a given day to the sum of cumulative discharges on a given day and cumulative deaths before j days is used to estimate the cure rate. Moreover, the case fatality ratio can also be estimated. After simulation calculations, j is statistically appropriate when it is 8-10, and it is also clinically appropriate. When j is 9, based on the available data, it is inferred that the cure rate of this epidemic is about 93% and the case fatality rate is about 7%. This method of estimating the cure rate can be used to evaluate the effectiveness of treatment in different medical schemes and different regions, and has great value and significance for decision-making in the epidemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data included in this study are available upon request by contact with the corresponding author.